STOCK TITAN

Oric Pharmaceuticals, Inc. - ORIC STOCK NEWS

Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.

Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to discovering and developing innovative therapies for the treatment of cancer. Headquartered in South San Francisco, California, Oric Pharmaceuticals was founded in 2014 and has since focused on addressing the challenging problem of cancer resistance to existing treatments.

The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor. This receptor has been identified as a key player in the resistance mechanisms against various classes of cancer therapeutics, particularly across solid tumors. By targeting this receptor, ORIC-101 aims to enhance the effectiveness of existing cancer treatments.

Another significant asset in Oric's pipeline is ORIC-533, an orally bioavailable small molecule inhibitor of CD73. CD73 plays a role in resistance to both chemotherapy and immunotherapy, and ORIC-533 is being developed to counteract this resistance, offering a potential new avenue for treating patients who do not respond to current therapies.

In addition to ORIC-101 and ORIC-533, the company is also developing ORIC-944 and ORIC-114, each targeting different mechanisms of cancer resistance. ORIC-944 has shown promise in initial Phase 1b data, and the company has outlined several anticipated milestones for these programs in the near future.

Oric Pharmaceuticals demonstrates a robust commitment to advancing the field of precision oncology. The company leverages its expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies to build a diverse pipeline of therapies. These efforts are supported by strategic partnerships and collaborations aimed at accelerating the development and commercialization of their treatment candidates.

Financially, Oric Pharmaceuticals has provided guidance and updates to keep stakeholders informed about their progress and strategic direction. For the latest news and developments, investors and interested parties are encouraged to stay tuned to the company's announcements.

Contact: Dominic Piscitelli, Chief Financial Officer

dominic.piscitelli@oricpharma.com

info@oricpharma.com

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
none
-
Rhea-AI Summary

ORIC Pharmaceuticals, a clinical-stage oncology company, announced participation in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 2:00 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 90 days post-event.

ORIC focuses on developing treatments that address mechanisms of therapeutic resistance, with product candidates including ORIC-533 for multiple myeloma, ORIC-114 targeting genetically defined cancers, and ORIC-944 for prostate cancer. The company operates from South San Francisco and San Diego, California.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
Rhea-AI Summary

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company, presented two preclinical posters at the 2023 AACR Annual Meeting. These presentations highlight the company’s ongoing development of ORIC-944, a PRC2 inhibitor currently in Phase 1 clinical trials targeting metastatic prostate cancer, and progress in their PLK4 inhibitor program aimed at addressing specific breast cancer mechanisms.

The findings revealed that ORIC-944 lowers H3K27me3 levels, supporting its biomarker strategy for the ongoing trial. In the PLK4 program, selective inhibitors exhibited synthetic lethality in TRIM37-amplified cancers. Both programs demonstrate ORIC's commitment to advancing targeted therapies against cancer resistance mechanisms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
-
Rhea-AI Summary

ORIC Pharmaceuticals reported significant advancements in its clinical pipeline, driven by three ongoing Phase 1b trials: ORIC-533 for multiple myeloma, ORIC-114 for EGFR/HER2-mutated cancers, and ORIC-944 for prostate cancer. A $25 million equity investment from Pfizer was secured, alongside a collaboration for a potential Phase 2 study of ORIC-533. As of December 31, 2022, the company had $228.2 million in cash and investments, expected to fund operations into the first half of 2025. The R&D expenses for 2022 totaled $61.7 million, reflecting strategic investments in product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.62%
Tags
-
Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC) announced two accepted abstracts for poster presentations at the 2023 AACR Annual Meeting, scheduled for April 14-19, 2023. The presentations will showcase preclinical biomarker results for ORIC-944, a selective PRC2 inhibitor in Phase 1 trials for metastatic prostate cancer, and data from its PLK4 inhibitor program. The biomarker strategy for ORIC-944 indicates significant H3K27me3 level reductions in response to treatment. Additionally, selective PLK4 inhibition shows enhanced synthetic lethality in certain cancer models. Both presentations aim to underline ORIC's innovative approach to overcoming therapeutic resistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
none
Rhea-AI Summary

ORIC Pharmaceuticals, a clinical stage oncology company, announced participation in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 2:00 p.m. ET. The discussion will be available via live webcast on the company's investor website, with replays accessible for 90 days post-event.

Focused on overcoming resistance in cancer, ORIC’s product pipeline includes ORIC-533, an inhibitor of CD73 for multiple myeloma; ORIC-114, targeting EGFR and HER2 in various cancers; and ORIC-944, an inhibitor of PRC2 for prostate cancer. Further information is available at www.oricpharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
conferences
-
Rhea-AI Summary

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced on February 1, 2023, the grant of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees. These inducement grants are part of the 2022 Inducement Equity Incentive Plan and are contingent on continued employment through each vesting date. The stock options' exercise price aligns with the closing price on the Grant Date. Vesting occurs over a span of time, with 25% vesting after one year and the remainder vesting monthly. The grants were approved by the Compensation Committee in compliance with Nasdaq regulations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary

ORIC Pharmaceuticals, a clinical stage oncology company, announced its management's participation in two key investor conferences in February 2023. The Guggenheim Healthcare Talks Oncology Day will feature a fireside chat on February 8 at 3:20 p.m. ET, followed by the Citi 2023 Virtual Oncology Leadership Summit on February 22 at 11:00 a.m. ET. Investors can access live webcasts through the company's website. ORIC is focused on developing treatments targeting mechanisms of resistance in cancer, with product candidates including ORIC-533, ORIC-114, and ORIC-944.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
conferences
Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC) announced key updates and milestones for its clinical pipeline on January 9, 2023. The company expects initial Phase 1b data for three ongoing trials—ORIC-533, ORIC-114, and ORIC-944—in the second half of 2023. Additionally, a new candidate was selected for its PLK4 synthetic lethal program targeting breast cancer. With $228 million in cash and investments, ORIC's funding is projected to last through the first half of 2025, supported by a recent $25 million investment from Pfizer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none

FAQ

What is the current stock price of Oric Pharmaceuticals (ORIC)?

The current stock price of Oric Pharmaceuticals (ORIC) is $8.21 as of December 20, 2024.

What is the market cap of Oric Pharmaceuticals (ORIC)?

The market cap of Oric Pharmaceuticals (ORIC) is approximately 550.4M.

What is Oric Pharmaceuticals, Inc.?

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to treat cancer by overcoming resistance to current treatments.

What is ORIC-101?

ORIC-101 is a small molecule antagonist of the glucocorticoid receptor, aimed at combating resistance in various solid tumors to enhance the effectiveness of cancer treatments.

What is ORIC-533?

ORIC-533 is an orally bioavailable small molecule inhibitor of CD73, developed to address resistance to chemotherapy and immunotherapy regimens.

Where is Oric Pharmaceuticals headquartered?

Oric Pharmaceuticals is headquartered in South San Francisco, California.

When was Oric Pharmaceuticals founded?

Oric Pharmaceuticals was founded in 2014.

What other products are in Oric Pharmaceuticals' pipeline?

In addition to ORIC-101 and ORIC-533, Oric Pharmaceuticals is developing ORIC-944 and ORIC-114, which target different cancer resistance mechanisms.

What are the core areas of expertise for Oric Pharmaceuticals?

The company focuses on hormone-dependent cancers, precision oncology, and key tumor dependencies.

How can I contact Oric Pharmaceuticals for more information?

You can contact Dominic Piscitelli, the Chief Financial Officer, at dominic.piscitelli@oricpharma.com or info@oricpharma.com for more information.

What is the company’s financial condition?

Oric Pharmaceuticals regularly provides financial guidance and updates to inform stakeholders about their progress and strategic direction.

What recent achievements has Oric Pharmaceuticals made?

Recent achievements include initial Phase 1b data for ORIC-944 and progress in developing ORIC-533 as a potent inhibitor of CD73.

Oric Pharmaceuticals, Inc.

Nasdaq:ORIC

ORIC Rankings

ORIC Stock Data

550.42M
59.77M
9.4%
102.1%
16.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO